WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentACETYLSALICYLIC ACID - MHRA confirms labelling change
View the documentACITRETIN - Warnings of depression added to label
View the documentASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
View the documentCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
View the documentDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
View the documentHUA FO - Presence of tadalafil
View the documentIODINE - Some products contain more than the RDA
View the documentLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
View the documentLINDANE - Additional warnings and medication guide added to label
View the documentNEFAZODONE - Regulatory status update
View the documentNIMESULIDE - Paediatric preparations banned in Bangladesh
View the documentPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
View the documentREPAGLINIDE - Contraindicated with gemfibrozil
View the documentRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
View the documentTELITHROMYCIN - Aggravation of myasthenia gravis
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsCURRENT CONCERNS
Open this folder and view contentsDRUGS OF INTEREST
Open this folder and view contentsFEATURE
 

NIMESULIDE - Paediatric preparations banned in Bangladesh

Bangladesh. The manufacture, distribution, sale and use of all dosage forms of nimesulide paediatric preparations were recently officially banned in Bangladesh. The banning of adult dosage forms of nimesulide preparations is now under active consideration of the Directorate of Drugs Administration of Bangladesh. A nation wide survey of reports of adverse effects with nimesulide is being conducted before taking a final decision with the adult usage formulations. Importation of nimesulide raw material has already been discontinued in order to discourage further manufacture of nimesulide preparations in the country.

Reference:
Communication to WHO, Geneva, from Director, Directorate of Drugs Administration, Ministry of Health and Family Welfare, Bangladesh, 11 Jun 2003.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019